NEWS | BEAM Alliance


Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

September 9, 2019 at 7:00 AM EDT

First IV and oral antibiotic with novel mechanism of action approved by the FDA in nearly two decades, targets the most common CABP pathogens and supports antibiotic stewardship

DUBLIN, Ireland, Sept. 09, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formulations of XENLETA™ (lefamulin) are now available in the U.S. through major specialty distributors. XENLETA was approved by the U.S. Food and Drug Administration (FDA) on August 19, 2019 for the treatment of adults with community-acquired bacterial pneumonia (CABP).

“The lack of innovative treatment options for CABP over the past two decades has resulted in increasing resistance in the most common bacteria causing CABP to multiple classes of antibiotics,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. “These drug-resistant pathogens are undermining clinicians’ ability to fight CABP and we are delighted to announce that XENLETA is now available as a short course, empiric monotherapy treatment option for adults with CABP.”

Full PR available here